Department of Vascular and Endovascular, Surgery University Hospital, Frankfurt am Main, Germany.
German Institute for Vascular Health Research (DIGG) of the German Society of Vascular Surgery and Vascular Medicine, Berlin, Germany.
Langenbecks Arch Surg. 2022 Dec;407(8):3691-3699. doi: 10.1007/s00423-022-02670-x. Epub 2022 Sep 12.
The influence of cancer development on long-term outcome after elective endovascular (EVAR) vs. open repair (OAR) of non-ruptured abdominal aortic aneurysms (AAA) was investigated.
Patient survival and cancer incidence were recorded for 18,802 patients registered with the AOK health insurance company in Germany who underwent EVAR (n = 14,218) and OAR (n = 4584) in the years 2010 to 2016 (men n = 16,086, women n = 2716). All patients were preoperatively and in their history cancer-free.
30.1% of EVAR and 27.6% of OAR patients (p ≤ .001) developed cancer after a follow-up period of up to 9 years (Kaplan-Meier estimated). Patients with cancer had a significantly less favorable outcome compared to patients with no cancer (HR 1.68; 95% CI 1.59-1.78, p < .001). After 9 years, the estimated survival of patients with and without cancer was 27.0% and 55.4%, respectively (p < .001). Survival of men and women did not differ significantly (HR 0.94; 95% CI 0.88-1.00, p = .061). In the Cox regression analysis (adjusted outcomes by operative approach, gender, age, and comorbidities), the postoperative cancer incidence was not significantly different between EVAR and OAR (HR 1.09; 95% CI 1.00-1.18, p = .051). However, EVAR showed an increased risk of postoperative development of abdominal cancer (HR 1.20; 95% CI 1.07-1.35, p = .002). 48.0% of all EVAR patients and 53.4% of all OAR patients survived in the follow-up period of up to 9 years. This difference was not significant (HR 0.96; 95% CI 0.91-1.02, p = .219).
Cancer significantly worsened the long-term outcome after EVAR and OAR, without significant differences between the two repair methods in the overall cancer incidence. However, the higher abdominal cancer incidence with EVAR can affect quality of life including oncological therapy and therefore should be considered when determining the indication for surgery, and the patient should be informed about it.
研究癌症发展对择期血管内(EVAR)与开放修复(OAR)治疗非破裂性腹主动脉瘤(AAA)患者长期预后的影响。
在德国 AOK 健康保险公司登记的 18802 名接受 EVAR(n=14218)和 OAR(n=4584)治疗的患者中,记录患者生存和癌症发病率,这些患者在 2010 年至 2016 年间接受了手术(男性 n=16086,女性 n=2716)。所有患者术前和病史均无癌症。
在最长 9 年的随访期间,EVAR 组和 OAR 组分别有 30.1%(p≤0.001)和 27.6%(p≤0.001)的患者发生癌症。与无癌症的患者相比,患有癌症的患者预后明显较差(HR 1.68;95%CI 1.59-1.78,p<0.001)。9 年后,有癌症和无癌症患者的估计生存率分别为 27.0%和 55.4%(p<0.001)。男性和女性的生存率无显著差异(HR 0.94;95%CI 0.88-1.00,p=0.061)。在 Cox 回归分析(通过手术方式、性别、年龄和合并症调整结果)中,EVAR 和 OAR 之间术后癌症发生率无显著差异(HR 1.09;95%CI 1.00-1.18,p=0.051)。然而,EVAR 显示术后发生腹部癌症的风险增加(HR 1.20;95%CI 1.07-1.35,p=0.002)。在最长 9 年的随访期间,所有 EVAR 患者中有 48.0%和所有 OAR 患者中有 53.4%存活。这一差异无统计学意义(HR 0.96;95%CI 0.91-1.02,p=0.219)。
癌症显著恶化了 EVAR 和 OAR 后的长期预后,两种修复方法的总体癌症发病率无显著差异。然而,EVAR 术后腹部癌症发病率较高会影响生活质量,包括肿瘤治疗,因此在确定手术指征时应考虑这一点,并告知患者。